

REAL-WORLD 12-MONTH MAINTENANCE PERIOD DATA IN ULCERATIVE COLITIS PATIENTS INITIATING FILGOTINIB THERAPY: FINDINGS FROM THE PROSPECTIVE FILGOCOLITIS STUDY ON CLINICAL EFFECTIVENESS AND NOVEL WEARABLE-DERIVED OUTCOMES

Sandra Plachta-Danielzik

UEG Week Berlin 2025

Poster

IBD

October 7, 2025

In a real-world observational study of 196 ulcerative colitis patients newly initiated on filgotinib, 44.3% achieved clinical remission and 41.4% achieved steroid-free remission at 12 months, with significant improvements in quality of life.

KEY POINTS

- At 12 months, clinical remission was achieved in 44.3% of patients and steroid-free remission in 41.4%, with treatment persistence of 59.7%.
- Clinical remission rates were similar between biologic-naïve and biologic-experienced patients (50.0% vs 43.4%, $p=0.79$).
- Among patients who responded at week 10, the remission rate at month 12 was 66.2%, compared to 29.2% remission at week 10 overall.
- Quality of life improved significantly, with median EQ-VAS scores increasing from 68 to 80 ($p<0.001$) and sIBDQ scores from 41.0 to 56.0 ($p<0.001$).
- Wearable device data showed patients in remission had fewer nocturnal steps than those not in remission (170 vs 342), consistent with reports of nocturnal bowel movements (0% vs 33.4%).

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/cdbde45e-a814-11f0-9117-0242ac140006>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.